AstraZeneca buys US biotech firm CinCor
Anglo-Swedish pharmaceuticals giant AstraZeneca on Monday agreed to buy US biotech company CinCor for $1.8 billion, expanding further into the field of heart and kidney drugs.
Jan 9, 2023
0
2
Anglo-Swedish pharmaceuticals giant AstraZeneca on Monday agreed to buy US biotech company CinCor for $1.8 billion, expanding further into the field of heart and kidney drugs.
Jan 9, 2023
0
2
Irish biotechnology company Elan rejected on Monday the latest takeover bid from US group Royalty Pharma worth about $7.9 billion (6.0 billion euros).
Jun 10, 2013
0
0
Pharmaceutical giant Pfizer said Friday that it hasn't given up on a deal after British drugmaker AstraZeneca flatly rejected its latest takeover bid, worth $106 billion.
May 2, 2014
1
0
Pharmaceutical company Mylan said Tuesday that it would take its offer to buy Perrigo directly to Perrigo shareholders following refusals by the company's management to engage in merger talks.
Sep 8, 2015
0
7
British pharmaceuticals giant AstraZeneca on Thursday said its net profits more than doubled in 2015, adding it expects lower sales this year on US patent expiry of cholesterol treatment Crestor.
Feb 4, 2016
0
0
Japanese drugs firm Takeda on Friday upped its takeover bid to $60.7 billion (49 billion euros) for Irish-based peer Shire, which has already rejected its previous three overtures.
Apr 20, 2018
0
0
British phamaceuticals giant AstraZeneca revealed Monday that it was in discussions over a deal with cancer drug maker Acerta Pharma.
Dec 14, 2015
0
1
AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee.
Oct 20, 2014
0
0
British drugmaker GlaxoSmithKline on Wednesday said it had gone hostile over its $2.6 billion (2.0 billion-euro) takeover bid for US research partner Human Genome Sciences Inc.
May 9, 2012
0
0
Botox maker Allergan formally rejected on Monday a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited offer worth nearly $46 billion undervalues the company and poses a significant risk to its growth prospects.
May 12, 2014
0
0